Suppr超能文献

哌甲酯对肥胖男性饮食的影响。

Influence of methylphenidate on eating in obese men.

作者信息

Leddy John J, Epstein Leonard H, Jaroni Jodie L, Roemmich James N, Paluch Rocco A, Goldfield Gary S, Lerman Caryn

机构信息

Department of Orthopedics, Sports Medicine Institute, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York 14214, USA.

出版信息

Obes Res. 2004 Feb;12(2):224-32. doi: 10.1038/oby.2004.29.

Abstract

OBJECTIVE

Rapid synaptic dopamine transport or reduced brain dopamine receptor signaling may influence energy intake. Methylphenidate, a dopamine reuptake inhibitor, increases brain synaptic dopamine and produces anorexia, suggesting that it may reduce energy intake. We investigated the effects of two doses of short-acting methylphenidate on energy intake over one meal in obese adult males.

RESEARCH METHODS AND PROCEDURES

Nine obese males (>85th BMI percentile) ingested a placebo or a moderate dose (0.5 mg/kg) or a high dose (1.0 mg/kg) of methylphenidate in a within-subject double-blind acute laboratory study. One hour after ingestion, pizza consumption was measured in a naturalistic laboratory setting.

RESULTS

Participants reduced energy intake by 23% for the moderate dose vs. the placebo (p < 0.02), but there was no significant difference for the high dose vs. the moderate dose (p > 0.05). Participants consumed 34% fewer kilocalories after ingesting the lowest effective dose of methylphenidate compared with placebo (725.7 +/- 404.5 vs.1095 +/- 271.1 kcal, p < 0.01). Seven of nine subjects responded to the moderate dose. The increase in perceived drug effect above placebo was correlated with the reduction in energy intake for both the moderate (r = -0.85, p = 0.004) and the high (r = -0.75 p = 0.021) doses. Hunger scores were not different across drug doses or placebo before drug administration.

DISCUSSION

Methylphenidate reduced energy intake of a highly palatable food over one meal by one-third in obese adult males. Dopamine transport inhibition may be an effective component of a comprehensive treatment for obesity.

摘要

目的

快速的突触多巴胺转运或大脑多巴胺受体信号传导减弱可能会影响能量摄入。哌甲酯,一种多巴胺再摄取抑制剂,可增加大脑突触多巴胺并导致厌食,这表明它可能会减少能量摄入。我们研究了两剂短效哌甲酯对肥胖成年男性一餐中能量摄入的影响。

研究方法和步骤

在一项受试者内双盲急性实验室研究中,9名肥胖男性(BMI百分位数>85)摄入了安慰剂、中等剂量(0.5mg/kg)或高剂量(1.0mg/kg)的哌甲酯。摄入后1小时,在自然主义实验室环境中测量披萨的摄入量。

结果

与安慰剂相比,中等剂量组参与者的能量摄入减少了23%(p<0.02),但高剂量组与中等剂量组之间无显著差异(p>0.05)。与安慰剂相比,摄入最低有效剂量的哌甲酯后,参与者消耗的千卡热量减少了34%(725.7±404.5 vs.1095±271.1千卡,p<0.01)。9名受试者中有7名对中等剂量有反应。与安慰剂相比,中等剂量(r=-0.85,p=0.004)和高剂量(r=-0.75,p=0.021)的哌甲酯在感知药物效果增加与能量摄入减少之间存在相关性。给药前,不同药物剂量或安慰剂组的饥饿评分无差异。

讨论

哌甲酯使肥胖成年男性一餐中高可口性食物的能量摄入减少了三分之一。多巴胺转运抑制可能是肥胖综合治疗的有效组成部分。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验